Scopolamine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1979
- First approval year
- 1979
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Scopolamine
- Molecular weight
- 303.36
- Structure (SMILES)
- CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
- scopolamine
- Scopolamine
- transderm scop
- Transderm scop
- (1R,2R,4S,5S,7S)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL (2S)-3-HYDROXY-2-PHENYLPROPANOATE
- 1r 2r 4s 5s 7s 9 methyl 3 oxa 9 azatricyclo 3 3 1 02 4 non 7 yl 2s 3 hydroxy 2 phenylpropanoate
- 6 beta 7 beta epoxy 1 alpha h 5 alpha h tropan 3 alpha ol tropate ester
- 6.BETA.,7.BETA.-EPOXY-1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (-)-TROPATE (ESTER)
- ATROPINE SULFATE IMPURITY F [EP IMPURITY]
- atropine sulfate impurity f ep impurity
- benzeneacetic acid alpha hydroxymethyl 1 alpha 2 beta 4 beta 5 alpha 7 beta 9 methyl 3 oxa 9 azatricyclo 3 3 1 02 4 non 7 yl ester alpha s
- benzeneacetic acid alpha hydroxymethyl 9 methyl 3 oxa 9 azatricyclo 3 3 1 02 4 non 7 yl ester 7 s 1 alpha 2 beta 4 beta 5 alpha 7 beta
- BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-
- BENZENEACETIC ACID, .ALPHA.(HYDROXYMETHYL)-,(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (.ALPHA.S)-
- hyoscine
- HYOSCINE
- HYOSCINE [EP IMPURITY]
- HYOSCINE [EP MONOGRAPH]
- HYOSCINE [MART.]
- Hyoscine [WHO-DD]
- hyoscine ep impurity
- hyoscine ep monograph
- hyoscine mart
- hyoscine who dd
- scopolamine
- Scopolamine
- Scopolamine (0.4mg)
- SCOPOLAMINE [HSDB]
- SCOPOLAMINE [MI]
And 11 more, listed on the interactive page.
- CAS registry numbers
- 51-34-3
- ChEMBL ID
- CHEMBL569713
- InChIKey
- STECJAGHUSJQJN-FWXGHANASA-N
- FDA ingredient codes (UNII)
- DL48G20X8X
- A04AD01
- A04AD51
- N05CM05
- S01FA02
Sources for recorded values
- 9601
- 56092
- Applicant
- BAXTER HLTHCARE CORP
- Approval date
- 31 Dec 1979
- Application number
- NDA017874
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- scopolamine
- Type
- Natural product
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M2 receptor
- Gene symbol
- CHRM2
- Protein identifier
- P08172
- Median affinity
- 8.7
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M4 receptor
- Gene symbol
- CHRM4
- Protein identifier
- P08173
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M5 receptor
- Gene symbol
- CHRM5
- Protein identifier
- P08912
- Median affinity
- 8.7
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M1 receptor
- Gene symbol
- CHRM1
- Protein identifier
- P11229
- Median affinity
- 9
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M3 receptor
- Gene symbol
- CHRM3
- Protein identifier
- P20309
- Median affinity
- 9.4
- Affinity units
- pKi
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
- Action type
- Antagonist
- Target
- Muscarinic acetylcholine receptor M1
- Protein identifier
- P11229
Open Targets mechanisms
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
- Action type
- Antagonist
- Target
- Muscarinic acetylcholine receptor M1
DrugCentral mechanisms
- Action type
- Antagonist
- Gene symbol
- CHRM1
- Protein identifier
- P11229
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003761
- Subject identifier
- D003865
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Postoperative Nausea and Vomiting
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004888
- Subject identifier
- D020250
- Condition
- Motion Sickness
- Highest recorded phase
- 4
- Condition identifier
- EFO:0006928
- Subject identifier
- D009041
- Condition
- Renal Colic
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001412
- Subject identifier
- D056844
- Condition
- Phobia, Social
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001917
- Subject identifier
- D000072861
- Condition
- Dementia
- Highest recorded phase
- 1
- Condition identifier
- HP:0000726
- Subject identifier
- D003704
- Condition
- Postoperative Nausea and Vomiting
- Highest recorded phase
- 4
- Condition identifier
- HP:0002017
- Subject identifier
- D020250
- Condition
- Nausea
- Highest recorded phase
- 4
- Condition identifier
- HP:0002018
- Subject identifier
- D009325
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depressive Disorder
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Alzheimer Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Bipolar Disorder
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004985
- Subject identifier
- D001714
- Condition identifier
- EFO_0003768
- Condition identifier
- EFO_0004320
- Condition identifier
- EFO_0004888
- Condition identifier
- EFO_0004888
- Highest recorded phase
- 4
- Condition identifier
- EFO_0006928
- Condition identifier
- EFO_0006928
- Highest recorded phase
- 4
- Condition identifier
- EFO_0007948
- Condition identifier
- EFO_1001412
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001917
- Highest recorded phase
- 1
- Condition identifier
- HP_0002017
- Condition identifier
- HP_0002017
- Highest recorded phase
- 4
- Condition identifier
- HP_0002018
- Condition identifier
- HP_0002018
- Highest recorded phase
- 4
- Condition identifier
- HP_0002307
- Highest recorded phase
- 3
- Condition identifier
- HP_0012531
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001247
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005485
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008575
- Event
- abnormal behaviour
- Reports
- 10
- Reporting signal score
- 13.4192
- Event
- agitation
- Reports
- 21
- Reporting signal score
- 28.8056
- Event
- akathisia
- Reports
- 9
- Reporting signal score
- 19.3856
- Event
- amnesia
- Reports
- 11
- Reporting signal score
- 13.3646
- Event
- anticholinergic syndrome
- Reports
- 22
- Reporting signal score
- 108.078
- Event
- anxiety
- Reports
- 17
- Reporting signal score
- 9.05414
- Event
- application site burn
- Reports
- 3
- Reporting signal score
- 8.65218
- Event
- application site erosion
- Reports
- 4
- Reporting signal score
- 17.4574
- Event
- application site erythema
- Reports
- 12
- Reporting signal score
- 33.5124
- Event
- application site hypersensitivity
- Reports
- 4
- Reporting signal score
- 18.437
- Event
- application site irritation
- Reports
- 11
- Reporting signal score
- 39.3328
- Event
- application site pain
- Reports
- 5
- Reporting signal score
- 9.05178
- Event
- application site pruritus
- Reports
- 7
- Reporting signal score
- 18.1345
- Event
- application site rash
- Reports
- 13
- Reporting signal score
- 45.22
- Event
- application site reaction
- Reports
- 6
- Reporting signal score
- 20.3399
- Event
- application site ulcer
- Reports
- 2
- Reporting signal score
- 8.55273
- Event
- balance disorder
- Reports
- 12
- Reporting signal score
- 13.0277
- Event
- brain damage
- Reports
- 3
- Reporting signal score
- 14.3443
- Event
- confusional state
- Reports
- 34
- Reporting signal score
- 41.7435
- Event
- delirium
- Reports
- 13
- Reporting signal score
- 18.7516
- Event
- disorientation
- Reports
- 30
- Reporting signal score
- 68.7211
- Event
- dizziness
- Reports
- 47
- Reporting signal score
- 31.388
- Event
- drug hypersensitivity
- Reports
- 22
- Reporting signal score
- 9.2504
- Event
- drug withdrawal syndrome
- Reports
- 11
- Reporting signal score
- 13.8033
- Event
- dry mouth
- Reports
- 22
- Reporting signal score
- 39.2209
And 34 more, listed on the interactive page.
- NCT00369915
- NCT04211961
- NCT00374478
- NCT02155309
- NCT02839135
- NCT03986905
- NCT03988530
- NCT04184115
- NCT04219982
- NCT04947423
- NCT04999449
- NCT05548270
- NCT05852730
- NCT05886660
- NCT00646061
- NCT01181310
- NCT01312844
- NCT01900301
- NCT03030105
- NCT03435003
- NCT03874130
- NCT04391361
- NCT04666701
- Dose
- 1 mg over 3 days
- Route
- Transdermal
- How often
- Up to 3 days
- Apply behind ear at least 4 hours before need
- Do not cut transdermal system
- Use only one at a time
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 62.3
- Calculated partition coefficient (ALogP)
- 0.92
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 22
- Molecular formula
- C17H21NO4
- Natural product
- Yes
- 0378-6470
- 0591-2258
- 10019-008
- 42858-150
- 45802-580
- 50742-505
- 50090-5349
- 50090-7188
- 63629-8450
- 63629-8451
- 63629-8452
- 68071-3994
- 69238-1662
- 70710-1846
- 70771-1787
- 71335-2718
- 71335-3013
- 71335-3014
- 71335-3015
- 72162-1419
- 72162-2453
Distribution coefficient (LogD)
- Median
- 0.28
- Mean
- 0.23
- Minimum
- 0.11
- Maximum
- 0.3
- Unit
- unitless
- Assays
- 3
- Standard deviation
- 0.104403
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 49
- Mean
- 49
- Minimum
- 49
- Maximum
- 49
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (72)
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
- A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
- A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
- A Phase III Confirmatory Study of K-237
- A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
- A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
- A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy
- Analgesic Efficacy of Intravenous Hyoscine-N-Butylbromide (HNB) in Abdominal Colic Associated With Acute Gastroenteritis
- Anesthetics in Rhytidoplasty - A Comparison Study
- Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI
- Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
- Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies
- Clozapine-induced Hypersalivation - Feasibility Trial
- Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
- Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
- Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Approved for (1)
- Motion sickness
In development for (7)
- Alzheimer disease Phase 1
- Amyotrophic lateral sclerosis Phase 2
- Bipolar disorder Phase 2
- Dementia Phase 1
- Depressive disorder Phase 2
- Major depressive disorder Phase 2
- Social phobia Phase 1
Other linked conditions (1)
- Nicotine dependence
Targets (1)
- CHRM1 Muscarinic acetylcholine receptor M1 antagonist